TIDMAGY
RNS Number : 3040T
Allergy Therapeutics PLC
23 November 2021
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Result of Annual General Meeting
23 November 2021 Allergy Therapeutics plc (AIM:AGY), the fully
integrated specialty pharmaceutical group specialising in allergy
vaccines, announces that, with the exception of resolution 10,
which failed to carry, all other resolutions proposed at the 2021
Annual General Meeting ("AGM") were duly passed by shareholders.
Voting was conducted by way of a poll.
Resolutions 1 to 9 (inclusive) were proposed as ordinary
resolutions and resolution 10 was proposed as a special resolution.
The results of the poll are outlined in the table below.
The Board acknowledges the failure to pass resolution 10 and is
disappointed in this outcome. The Board considers the flexibility
afforded by these authorities to be in the best interests of the
Company and shareholders and notes that this resolution has
received support at previous AGMs. However, the Board remains
committed to continuing an open and transparent dialogue and will,
accordingly, seek to continue to engage with shareholders regarding
their views in this area.
Resolution For: %age Against: %age Withheld
1. To receive
a copy of the
Annual Report
for the year
ended 30 June
2021 176,577,712 99.99 0 0 0
------------ ------ ------------ ------ ----------
2. To approve
the Directors'
Remuneration
Report 174,524,577 98.86 1,989,308 1.13 63,827
------------ ------ ------------ ------ ----------
3. To re-appoint
Mary Tavener
as a Director 176,161,541 99.98 7,089 0.01 409,082
------------ ------ ------------ ------ ----------
4. To re-appoint
Scott Leinenweber
as a Director 173,381,457 98.41 2,787,173 1.58 409,082
------------ ------ ------------ ------ ----------
5. To re-appoint
Tunde Otulana
as a Director 176,161,541 99.98 7,089 0.01 409,082
------------ ------ ------------ ------ ----------
6. To re-appoint
Peter Jensen
as a Director 173,387,212 98.84 2,022,948 1.15 1,167,552
------------ ------ ------------ ------ ----------
7. To appoint
BDO LLP as auditors
of the Company 176,142,079 99.97 32,806 0.02 402,827
------------ ------ ------------ ------ ----------
8. To authorise
the Directors
to determine
the Auditors
remuneration 176,577,712 99.99 0 0 0
------------ ------ ------------ ------ ----------
9. To authorise
the Directors
to allot unissued
share capital
up to a specified
amount (s551) 176,565,019 99.98 11,693 0.01 1,000
------------ ------ ------------ ------ ----------
10 Special Resolution:
To disapply pre-emption
provisions of
s561(1) of the
CoAct 2006 up
to a specified
amount 37,107,171 21.00 139,469,541 78.99 1,000
------------ ------ ------------ ------ ----------
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines, that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.600 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGFEEFEDEFSEIF
(END) Dow Jones Newswires
November 23, 2021 07:54 ET (12:54 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024